This report provides comprehensive information on the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium Infections and special features on late-stage and discontinued projects.
1. Hexa Reports
Market Research Reports and Insightful Company Profiles
Global Vancomycin-Resistant Enterococcus Faecium Infections
Industry 2015 Market Share, Size, Industry Profile, Market Prize,
Forecast and Overview
Global Markets Direct's, 'Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H1
2015', provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections's therapeutic
pipeline.
This report provides comprehensive information on the therapeutic development for Vancomycin-
Resistant Enterococcus Faecium Infections, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and
molecule type, along with latest updates, and featured news and press releases. It also reviews key
players involved in the therapeutic development for Vancomycin-Resistant Enterococcus Faecium
Infections and special features on late-stage and discontinued projects.
Browse Detail Report With TOC @ http://www.hexareports.com/report/vancomycin-resistant-
enterococcus-faecium-infections-pipeline-review-h1-2015/details
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy
areas and nearly 3,000 indications. The report is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third
party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the
report undergoes periodic updation following a stringent set of processes that ensures that all the
2. Hexa Reports
Market Research Reports and Insightful Company Profiles
profiles are updated with the latest set of information. Additionally, processes including live news &
deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain
competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce
first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance
of data for the indicated disease.
Scope
The report provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant
Enterococcus Faecium Infections
The report reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental
activities
The report reviews key players involved in the therapeutics development for Vancomycin-
Resistant Enterococcus Faecium Infections and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Vancomycin-Resistant Enterococcus Faecium Infections products under
development by companies and universities/research institutes based on information derived
from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-
registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of
target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate
effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-
strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for
Vancomycin-Resistant Enterococcus Faecium Infections
3. Hexa Reports
Market Research Reports and Insightful Company Profiles
Plan mergers and acquisitions effectively by identifying key players of the most promising
pipeline
Devise corrective measures for pipeline projects by understanding Vancomycin-Resistant
Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and Scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the
factors that drove them from pipeline
Request A Sample copy of This Report @ http://www.hexareports.com/sample/47458
Table Of Content
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Vancomycin-Resistant Enterococcus Faecium Infections Overview 9
Therapeutics Development 10
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Overview 10
Pipeline Products for Vancomycin-Resistant Enterococcus Faecium Infections - Comparative Analysis 11
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Development by
Companies 12
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics under Investigation by
Universities/Institutes 14
Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Products Glance 15
Clinical Stage Products 15
Early Stage Products 16
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Development by Companies 17
Vancomycin-Resistant Enterococcus Faecium Infections - Products under Investigation by
Universities/Institutes 19
Vancomycin-Resistant Enterococcus Faecium Infections - Companies Involved in Therapeutics
Development 20
Alchemia Limited 20
Alvogen, Inc. 21
Aphios Corporation 22
Cellceutix Corporation 23
Enanta Pharmaceuticals, Inc. 24
Helix BioMedix, Inc. 25
LegoChem Biosciences, Inc 26
Lytix Biopharma AS 27
4. Hexa Reports
Market Research Reports and Insightful Company Profiles
MGB Biopharma Limited 28
Microbiotix, Inc. 29
MicuRx Pharmaceuticals, Inc. 30
Nabriva Therapeutics AG 31
NovaBay Pharmaceuticals, Inc. 32
NovoBiotic Pharmaceuticals, LLC 33
Oragenics, Inc. 34
Sealife PHARMA GMBH 35
Sentinella Pharmaceuticals, Inc. 36
TAXIS Pharmaceuticals, Inc. 37
Wockhardt Limited 38
Vancomycin-Resistant Enterococcus Faecium Infections - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Target 40
Assessment by Mechanism of Action 42
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
Browse Full Report @ http://www.hexareports.com/report/vancomycin-resistant-enterococcus-
faecium-infections-pipeline-review-h1-2015/details
About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom
research and consulting services to a host of key industries across the globe. We offer comprehensive
business intelligence in the form of industry reports which help our clients obtain clarity about their
business environment and enable them to undertake strategic growth initiatives.
Contact Information:
Ryan Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
Our Blogs: http://hexareports.blogspot.in